Health Care · Biological Products, (No Diagnostic Substances) · OTC · CIK 1870404 · FYE Dec 31 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $0.01Day +27.84%Mkt cap $559,3941Y −99.8%Off 52W high −99.9%Vol (1Y) 202.1%
Daily closing price, split-adjusted to the current basis; 2.4y shown of 608 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest0.0% of sh out |
| Days to cover1.0d |
| Next report (est.)2026-08-12 |
Short interest is FINRA semi-monthly, settlement 2026-07-15.
| Earnings (TTM)-$20.7M |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−81.5% |
| 1Y−99.8% |
| Since incept. (ann.)−99.6% |
Total return through 2026-07-28 · series begins 2024-02-15. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)202.1% |
| Ann. volatility (3Y)254.7% |
| Sharpe (1Y)−1.48 |
| Sharpe (3Y)−1.00 |
| Max drawdown (1Y)−99.9% |
| Max drawdown (3Y)−100.0% |
| Beta (3Y vs SPY)2.00 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
No 13F holders on file for CERO.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | −$0.20 | — | — | — |
| 2025-09-30 | 2025-11-19 | −$9.10 | — | — | — |
| 2025-06-30 | 2025-08-22 | −$61.71 | — | — | — |
| 2025-03-31 | 2025-05-15 | — | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-12 is ESTIMATED from filing cadence (median gap 89d) — not company-confirmed.
